We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
+15.39%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$3.55B
AUM Growth
+$396M
Cap. Flow
+$31.1M
Cap. Flow %
0.88%
Top 10 Hldgs %
73.18%
Holding
30
New
2
Increased
6
Reduced
5
Closed
–

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$35.1M
2
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$7.62M
3
CDTX
Cidara Therapeutics
CDTX
+$7.01M
4
TSRO
TESARO, Inc.
TSRO
+$3.58M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$3.28M

Top Sells

Rank Stock Value
1
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$11.1M
2
PBYI icon
Puma Biotechnology
PBYI
+$7.06M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$5.8M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$5.67M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$2.54M

Sector Composition

Rank Sector Weight
1 Healthcare 86.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$432M 12.18%
3,609,298
+20,000
+0.6% +$2.31M
INCY icon
2
Incyte
INCY
$25.3B
$407M 11.46%
3,750,406
– –
IONS icon
3
Ionis Pharmaceuticals
IONS
$8.93B
$404M 11.39%
6,529,838
-105,000
-2% -$5.67M
GILD icon
4
Gilead Sciences
GILD
$165B
$281M 7.91%
2,774,596
– –
RDUS
5
DELISTED
Radius Health, Inc.
RDUS
$263M 7.41%
4,272,140
– –
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
$197M 5.56%
1,034,428
– –
NBIX icon
7
Neurocrine Biosciences
NBIX
$18.2B
$177M 4.97%
3,121,552
-50,000
-2% -$2.54M
VRTX icon
8
Vertex Pharmaceuticals
VRTX
$123B
$172M 4.84%
1,365,445
– –
AGIO icon
9
Agios Pharmaceuticals
AGIO
$2.09B
$140M 3.95%
2,159,921
+50,000
+2% +$3.28M
MDVN
10
DELISTED
MEDIVATION, INC.
MDVN
$125M 3.51%
2,581,112
– –
HALO icon
11
Halozyme
HALO
$9.87B
$122M 3.43%
7,029,832
+100,000
+1% +$1.59M
REGN icon
12
Regeneron Pharmaceuticals
REGN
$73B
$111M 3.13%
205,000
– –
ALNY icon
13
Alnylam Pharmaceuticals
ALNY
$38.2B
$107M 3%
1,132,499
– –
NVAX icon
14
Novavax
NVAX
$1.2B
$69.9M 1.97%
416,500
– –
TSRO
15
DELISTED
TESARO, Inc.
TSRO
$64.3M 1.81%
1,229,582
+75,000
+6% +$3.58M
CEMP
16
DELISTED
Cempra, Inc.
CEMP
$62M 1.75%
1,991,900
+100,000
+5% +$2.78M
JUNO
17
DELISTED
Juno Therapeutics, Inc.
JUNO
$57.4M 1.62%
1,305,000
– –
ALDR
18
DELISTED
Alder Biopharmaceuticals
ALDR
$49.9M 1.41%
1,510,150
– –
KITE
19
DELISTED
Kite Pharma, Inc.
KITE
$46.2M 1.3%
750,000
– –
PTCT icon
20
PTC Therapeutics
PTCT
$6.18B
$42.2M 1.19%
1,302,912
– –
SAGE
21
DELISTED
Sage Therapeutics
SAGE
$41.3M 1.16%
+708,663
New +$35.1M
ICPT
22
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$38.2M 1.08%
255,719
+45,000
+21% +$7.62M
PBYI icon
23
Puma Biotechnology
PBYI
$399M
$33.9M 0.95%
431,991
-90,000
-17% -$7.06M
PRTA icon
24
Prothena Corp
PRTA
$452M
$21.8M 0.61%
320,000
– –
INFI
25
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$21.2M 0.6%
2,700,737
– –
1
2

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 9.56% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 0.35% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q4 2015 Portfolio in Review

As of Q4 2015, BB Biotech held 30 positions worth $3.55B, up 13% from $3.15B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

BB Biotech's Q4 2015 filing shows 2 new, 6 increased and 5 reduced positions. Its largest new stake was Sage Therapeutics: 708,663 shares worth $41.3M. The largest sale was Tetraphase Pharmaceuticals, Inc., an estimated $11.1M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 84% a quarter earlier.

  • BB Biotech's largest Q4 2015 buy was Sage Therapeutics: 708,663 shares worth $41.3M.
  • BB Biotech added most to Intercept Pharmaceuticals, Inc. in Q4 2015, an estimated $7.62M increase.
  • BB Biotech's biggest Q4 2015 reduction was Tetraphase Pharmaceuticals, Inc., cutting an estimated $11.1M.
  • BB Biotech's ten largest holdings make up 73% of its $3.55B portfolio in Q4 2015.
  • BB Biotech opened 2 new positions and closed 0 in Q4 2015.
  • BB Biotech's portfolio value rose 13% quarter-over-quarter to $3.55B.

Based on BB Biotech's 13F filing for Q4 2015, filed 9 Feb 2016.